The ability to act powerful rests on the ease with which individuals retrieve memories of feeling powerful
NEW YORK — The simple act of thinking back to a time when you felt powerful is linked to better performances in job interviews, presentations and exams. A new study by researchers at Columbia Business School and INSEAD published in the journal Social Cognition finds that a key factor shaping when these effects are likely to occur rests on the ease with which people can retrieve an experience of power.
The ability to act powerful rests on the ease with which individuals retrieve memories of feeling powerful
NEW YORK — The simple act of thinking back to a time when you felt powerful is linked to better performances in job interviews, presentations and exams. A new study by researchers at Columbia Business School and INSEAD published in the journal Social Cognition finds that a key factor shaping when these effects are likely to occur rests on the ease with which people can retrieve an experience of power.
At corporate gathering, dean shares updates on faculty research, academic initiatives, and the successful capital campaign for the new Manhattanville campus.
The Paul Milstein Center for Real Estate is pleased to announce that Luiza Loureiro ’17, Morgan Mann ’17 and Mandy Yeung ’18 have been granted awards by WX New York Women Executives in Real Estate!
Steve Winograd `82, Managing Director of PennantPark Investment Advisers, has recently joined the Advisory Board of the Private Equity Program at Columbia Business School.
The Tamer Fund for Social Ventures recently completed its fourth funding cycle and selected four new early-stage ventures to add to the portfolio.
The following Tamer Fund for Social Venture awardees were selected out of almost 100 applicants after participating in an application screening round, a due diligence process with student teams as part of a Business School course, and a final pitch to the Fund’s Investment Board:
Stephen Doberstein is senior vice president and chief scientific officer at a biotech firm that is developing an opioid designed to offer pain relief without the feeling of euphoria that can lead to addiction.